Q32 Bio Inc. (0T6G.L)

24.93 +1.07 (+4.47%) At close: 02:53PM BST

Q32 Bio Inc.

830 Winter Street
Waltham, MA 02451
United States
781 999 0232
https://www.q32bio.com

Sector(s): 
Industry: 
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Jodie Pope Morrison	CEO, Secretary & Director	852.63k	N/A	1975
Dr. Shelia M. Violette Ph.D.	Co-founder, Chief Scientific Officer & President of Research	619.93k	N/A	1961
Dr. Jason A. Campagna M.D., Ph.D.	Chief Medical Officer	680.93k	N/A	1971
Mr. Lee H. Kalowski M.B.A.	CFO, President & Treasurer	N/A	N/A	1981
Dr. Saul Fink Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. David Appugliese J.D.	Senior VP & Head of People	N/A	N/A	N/A
Ms. Maria Marzilli M.P.H.	Executive Vice President of Corporate Strategy & Program Operations	N/A	N/A	N/A
Ms. Kathryn E. Golden M.B.A.	Head of Chemistry, Manufacturing & Controls	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Corporate governance

Q32 Bio Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.